{"alanine aminotransferase increased": 6.62, "alveolar soft part sarcoma": 3233.72, "amylase increased": 5.84, "ascites": 2.55, "aspartate aminotransferase increased": 5.46, "blood bilirubin increased": 9.16, "blood pressure increased": 2.13, "blood thyroid stimulating hormone increased": 11.45, "cardiac failure": 2.22, "clear cell renal cell carcinoma": 506.71, "decreased appetite": 3.59, "diarrhoea": 2.92, "disease progression": 3.9, "drug intolerance": 3.34, "drug-induced liver injury": 6.89, "haemoptysis": 3.05, "hair colour changes": 75.32, "hepatic enzyme increased": 2.25, "hepatic failure": 3.38, "hepatic function abnormal": 6.37, "hepatotoxicity": 25.05, "hyperbilirubinaemia": 10.85, "hypertension": 5.89, "hypertransaminasaemia": 6.92, "hypothyroidism": 8.45, "intestinal perforation": 9.83, "jaundice": 3.47, "liver function test abnormal": 2.66, "liver function test increased": 5.78, "liver injury": 4.33, "maligt neoplasm progression": 39.76, "metastases to bone": 15.63, "metastases to central nervous system": 18.63, "metastases to liver": 13.43, "metastases to lung": 63.81, "metastases to lymph nodes": 21.77, "metastatic renal cell carcinoma": 84.07, "mucosal inflammation": 3.75, "nephrotic syndrome": 5.59, "neutropenia": 2.33, "osteosarcoma metastatic": 868.04, "palmar-plantar erythrodysaesthesia syndrome": 22.29, "platelet count decreased": 2.94, "pleural effusion": 4.03, "pneumothorax": 36.23, "posterior reversible encephalopathy syndrome": 15.03, "product use in unapproved indication": 9.15, "proteinuria": 10.41, "pulmonary mass": 5.65, "renal cell carcinoma": 40.2, "soft tissue sarcoma": 392.81, "stomatitis": 2.08, "therapeutic response decreased": 6.69, "therapy partial responder": 16.12, "thrombocytopenia": 2.79, "transaminases increased": 9.24, "treatment failure": 2.11}